These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27855072)

  • 1. Clinical Benefit of Appropriate Empirical Fluoroquinolone Therapy for Adults with Community-Onset Bacteremia in Comparison with Third-Generation-Cephalosporin Therapy.
    Lee CC; Wang JL; Lee CH; Hsieh CC; Hung YP; Hong MY; Tang HJ; Ko WC
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing the therapeutic efficacies of third-generation cephalosporins and broader-spectrum β-lactams as appropriate empirical therapy in adults with community-onset monomicrobial Enterobacteriaceae bacteraemia: a propensity score matched analysis.
    Lee CH; Hsieh CC; Hong MY; Hung YP; Ko WC; Lee CC
    Int J Antimicrob Agents; 2017 May; 49(5):617-623. PubMed ID: 28315452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Propensity score-matched analysis comparing the therapeutic efficacies of cefazolin and extended-spectrum cephalosporins as appropriate empirical therapy in adults with community-onset Escherichia coli, Klebsiella spp. and Proteus mirabilis bacteraemia.
    Hsieh CC; Lee CH; Hong MY; Hung YP; Lee NY; Ko WC; Lee CC
    Int J Antimicrob Agents; 2016 Dec; 48(6):712-718. PubMed ID: 27836382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical benefits of antimicrobial de-escalation in adults with community-onset monomicrobial Escherichia coli, Klebsiella species and Proteus mirabilis bacteremia.
    Lee CC; Wang JL; Lee CH; Hung YP; Hong MY; Tang HJ; Ko WC
    Int J Antimicrob Agents; 2017 Sep; 50(3):371-376. PubMed ID: 28694235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial effects of early empirical administration of appropriate antimicrobials on survival and defervescence in adults with community-onset bacteremia.
    Lee CC; Lee CH; Yang CY; Hsieh CC; Tang HJ; Ko WC
    Crit Care; 2019 Nov; 23(1):363. PubMed ID: 31747950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Benefit of Empiric High-Dose Levofloxacin Therapy for Adults With Community-onset Enterobacteriaceae Bacteremia.
    Lee CC; Yang CY; Lee CH; Hsieh CC; Hong MY; Tang HJ; Ko WC
    Clin Ther; 2019 Oct; 41(10):1996-2007. PubMed ID: 31421908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High variability among Emergency Departments in 3rd-generation cephalosporins and fluoroquinolones use for community-acquired pneumonia.
    Batard E; Lecadet N; Goffinet N; Hardouin JB; ; Lepelletier D; Potel G; Montassier E
    Infection; 2015 Dec; 43(6):681-9. PubMed ID: 25998004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empirical third-generation cephalosporin therapy for adults with community-onset Enterobacteriaceae bacteraemia: Impact of revised CLSI breakpoints.
    Hsieh CC; Lee CH; Li MC; Hong MY; Chi CH; Lee CC
    Int J Antimicrob Agents; 2016 Apr; 47(4):297-303. PubMed ID: 27005458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative-Effectiveness of Oral Beta-Lactams and Fluoroquinolones for Stepdown Therapy in Patients with Enterobacterales Bloodstream Infections: A Retrospective Cohort Study.
    Bjork L; Hopkins T; Yang L; Teng C; Jones X; Cadena J; Walter E; Frei CR
    Int J Med Sci; 2023; 20(4):437-443. PubMed ID: 37057217
    [No Abstract]   [Full Text] [Related]  

  • 10. Antimicrobial escalation is not beneficial for Gram-negative bacteremia in adults who remained critically ill after appropriate empirical therapy.
    Ho CY; Lee CH; Yang CY; Hsieh CC; Ko WC; Lee CC
    J Infect Chemother; 2020 Sep; 26(9):933-940. PubMed ID: 32386930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes.
    Freeman JT; McBride SJ; Nisbet MS; Gamble GD; Williamson DA; Taylor SL; Holland DJ
    Int J Infect Dis; 2012 May; 16(5):e371-4. PubMed ID: 22401750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empirical use of fluoroquinolones improves the survival of critically ill patients with tuberculosis mimicking severe pneumonia.
    Tseng YT; Chuang YC; Shu CC; Hung CC; Hsu CF; Wang JY
    Crit Care; 2012 Oct; 16(5):R207. PubMed ID: 23098258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibiotic resistance in adult female patients hospitalized for acute pyelonephritis: rates and predicting factors.
    Etienne M; Van Elslande H; Choplin-Renard J; Pestel-Caron M; Caron F
    Med Mal Infect; 2014 May; 44(5):217-22. PubMed ID: 24787633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Timing of appropriate empirical antimicrobial administration and outcome of adults with community-onset bacteremia.
    Lee CC; Lee CH; Hong MY; Tang HJ; Ko WC
    Crit Care; 2017 May; 21(1):119. PubMed ID: 28545484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features and therapeutic implications of 104 episodes of monomicrobial Aeromonas bacteraemia.
    Ko WC; Lee HC; Chuang YC; Liu CC; Wu JJ
    J Infect; 2000 May; 40(3):267-73. PubMed ID: 10908022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: A propensity score analysis.
    De la Calle C; Ternavasio-de la Vega HG; Morata L; Marco F; Cardozo C; García-Vidal C; Del Rio A; Cilloniz C; Torres A; Martínez JA; Mensa J; Soriano A
    J Infect; 2018 Apr; 76(4):342-347. PubMed ID: 29360520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of fluoroquinolone resistance in Gram-negative bloodstream infections on healthcare utilization.
    Brigmon MM; Bookstaver PB; Kohn J; Albrecht H; Al-Hasan MN
    Clin Microbiol Infect; 2015 Sep; 21(9):843-9. PubMed ID: 26003282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features and impact of empirical therapy in cirrhotic adults with community-onset bacteremia.
    Hsieh CC; Lee CC; Chan TY; Hong MY; Chi CH; Ko WC
    Am J Emerg Med; 2015 Feb; 33(2):222-8. PubMed ID: 25498529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of Fluoroquinolone Resistance in Gram-Negative Bacteria Causing Bloodstream Infections.
    Dan S; Shah A; Justo JA; Bookstaver PB; Kohn J; Albrecht H; Al-Hasan MN
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2265-72. PubMed ID: 26833166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients with community-acquired bacteremia of unknown origin: clinical characteristics and usefulness of microbiological results for therapeutic issues: a single-center cohort study.
    Courjon J; Demonchy E; Degand N; Risso K; Ruimy R; Roger PM
    Ann Clin Microbiol Antimicrob; 2017 May; 16(1):40. PubMed ID: 28526094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.